Copyright
©The Author(s) 2021.
World J Diabetes. Apr 15, 2021; 12(4): 331-343
Published online Apr 15, 2021. doi: 10.4239/wjd.v12.i4.331
Published online Apr 15, 2021. doi: 10.4239/wjd.v12.i4.331
Ref. | Participants | Design and protocol | Exercise intensity | Main results |
Mackenzie et al[63] (2011)1 | n = 8; sex: Male; age: 58 ± 4.0 yr; BMI: 29.2 ± 6.7 kg/m2 | (1) 60 min rest in normoxia; (2) 60 min rest in hypoxia normobaric hypoxia (FiO2: 14.6%, simulated altitude: ca.3100 m); (3) 60 min cycling in normoxia; and (4) 60 min cycling in hypoxia (normobaric hypoxia: FiO2: 14.6%) | (3) and (4): 90% lactate threshold | Blood lactate: ↔ (1), (2); ↑ (3), (4). Blood glucose: ↔ (1); ↓ (2), (3), (4). Insulin sensitivity (during glucose tolerance test): (4) > (3) > (2) > (1) |
Mackenzie et al[46] (2012)1 | n = 8; sex: Male; age: 58.7 ± 2.2 yr; BMI: 28.3 ± 2.1 kg/m2 | (1) 60 min continuous cycling in hypoxia (normobaric hypoxia: FiO2: 14.7%, simulated altitude: ca.3100 m); (2) 60 min interval training with passive recovery (5:5 min) in hypoxia (normobaric hypoxia: FiO2: 14.7%); and (3) 60 min interval training with passive recovery (5:5 min) in normoxia | (1): 90% lactate threshold; (2): 120% lactate threshold; (3): 120% lactate threshold | HR and blood lactate: ↑ (1), (2), (3). Blood glucose decrease (pre- to post-exercise): (1) > (2). Glucose disappearance: ↑ (1); ↔ (2), (3). HOMA-IR index improved after 24 h: ↑ (1), (2); ↔ (3); after 48 h: ↑ (1); ↔ (3) |
Brinkmann et al[76] (2017)2 | n = 8; sex: Male; age: 58.0 ± 15.0 yr; BMI: 33.0 ± 6.0 kg/m2 | 40 min cycling: (1) Normoxia; (2) Hypoxia (normobaric hypoxia: FiO2: 14%, simulated altitude: ca. 3400 m); and (3) Hypoxia (normobaric hypoxia: FiO2: 14%) + hyperoxia (normobaric hyperoxia: FiO2: 30%) intervals (5:5 min) | Blood lactate: 2.5 mmol/L | Blood lactate (post-exercise lower): (3) > (2). BORG RPE: ↔ (1), (2), (3). Pro-angiogenic factors: VEGF: ↑ (2), (3). Anti-angiogenic factor: endostatin: ↑ (2), (3) |
- Citation: Kim SW, Jung WS, Chung S, Park HY. Exercise intervention under hypoxic condition as a new therapeutic paradigm for type 2 diabetes mellitus: A narrative review. World J Diabetes 2021; 12(4): 331-343
- URL: https://www.wjgnet.com/1948-9358/full/v12/i4/331.htm
- DOI: https://dx.doi.org/10.4239/wjd.v12.i4.331